TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06233721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online education
Description: Education content was prepared by the researchers by reviewing the literature. Education content included topics such as oral anticoagulant (OAC) medication introduction, OAC medication use, duration of use, most frequently seen side effects, interaction with other medications and foods, and points to consider while using the medication. While preparing the education content, expert opinions of five nurse academicians were taken. Evaluation of expert opinion was made through the form for Evaluation of the Appropriateness of Printed Materials and Discern. This education content created was provided to the face-to-face and online education groups in one session. Education sessions lasted approximately for 25-30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-face education
Description: Education content was prepared by the researchers by reviewing the literature. Education content included topics such as OAC medication introduction, OAC medication use, duration of use, most frequently seen side effects, interaction with other medications and foods, and points to consider while using the medication. While preparing the education content, expert opinions of five nurse academicians were taken. Evaluation of expert opinion was made through the form for Evaluation of the Appropriateness of Printed Materials and Discern. This education content created was provided to the face-to-face and online education groups in one session. Education sessions lasted approximately for 25-30 minutes.
Study: NCT05145062

Intervention type: DRUG
Intervention: BIVV003
Description: Solution for intravenous administration

Intervention type: DRUG
Intervention: ST-400
Description: Solution for intravenous administration
Study: NCT06461403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler Trainer System
Description: The system consists of an instrumented training inhaler capable of accurately measuring the real-time inspiratory airflow achieved by the user when they perform their inhale maneuver. The inhaler trainer system consists of a detachable/disposable mouthpiece and a reusable electronics module. The electronics module measures flow/pressure achieved by the patient and wirelessly transmits this data to a PC. The PC software analyzes the real-time inhalation flow data to enable the monitoring of the following quantities: Flow Rate, Duration, and Maximum Pressure Slope. These quantities will be used in the computation of the assessment metric, providing the user with real-time feedback about their inhalation technique. In addition, the software includes features to support the human study and provides fully functional inhaler education features for the expert test evaluators.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Initial Inhaler Use Assessment
Description: Patients will undergo an initial assessment of their respiratory inhaler technique for their respiratory inhaler devices using device-specific checklists

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initial Inhaler Use Assessment
Description: Patients will undergo an initial assessment of their respiratory inhaler technique for their respiratory inhaler devices using device-specific checklists

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhaler Use Instruction
Description: Participants will then be given step-by-step verbal instructions and a copy of written instructions by the trained educator describing appropriate inhaler technique for their respiratory inhalers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhaler Use Instruction
Description: Participants will then be given step-by-step verbal instructions and a copy of written instructions by the trained educator describing appropriate inhaler technique for their respiratory inhalers.
Study: NCT05107050

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline and Amorphous gel
Description: Saline - sodium chloride and water Amorphous hydrogel dressings are formulations of water, polymers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIAKOS™ Antimicrobial Skin & Wound Cleanser, BIAKŌS Antimicrobial Wound Gel
Description: Antimicrobial Skin \& Wound Cleanser helps in the mechanical removal of debris and foreign material from the skin, wound, or application site.~BIAKŌS Antimicrobial Wound Gel provides a moist environment to wound surfaces. BIAKŌS Antimicrobial Wound Gel is a safe and gentle colorless gel. The gel provides preservative properties through the antimicrobial PHMB. BIAKŌS Antimicrobial Wound Gel: • Resists microbial colonization within the gel during shelf storage. • Provides an amorphous gel covering. • Facilitates autolytic debridement through a moist wound environment. Wounds experience some level of autolytic debridement in which the body's own enzymes breakdown necrotic tissue.
Study: NCT05532254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole 10 mg tablet
Description: an immediate-release tablet containing 10 mg Aripiprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abilify® 10 mg tablet
Description: an immediate-release tablet containing 10 mg Aripiprazole
Study: NCT06494605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM)
Description: The Early Start Denver Model (ESDM) is an early naturalistic and behavioural intervention for children with initial signs of neurodivergence or on the autism spectrum between the ages of 12-48 months. This early intervention aims to increase the rates of development in several domains and to decrease the characteristics of autism conditions that hinder children's ability to learn from everyday experiences and interactions.
Study: NCT04756856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle-target oral nutritional supplementation
Description: Patients will receive daily for 12 weeks two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, and 800 IU vitamin D. Patients will be also followed for 12 weeks after the suspension of supplementation.
Study: NCT05251480

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: debridement, wound dressings, offloading

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DermGEN™
Description: Decellularized human dermal matrix created from donated human skin
Study: NCT05623046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: 8 one-on-one teletherapy training sessions to enhance emotional skills. Teletherapy sessions will last approximately 60-90 minutes
Study: NCT04646421

Intervention type: BEHAVIORAL
Intervention: Motivational telephone intervention
Description: Motivational telephone intervention to high-risk gamblers, aiming to stimulate them to reduce gambling, quit gambling, or to seek peer support or treatment.

Intervention type: BEHAVIORAL
Intervention: Motivational telephone intervention
Description: Motivational telephone intervention to high-risk gamblers, aiming to stimulate them to reduce gambling, quit gambling, or to seek peer support or treatment.
Study: NCT06530147

Intervention type: OTHER
Intervention: Transversalis Fascia Plane Block
Description: One-side ultrasound (US)-guided Transversalis fascia plane (TFP) block with 0.25% bupivacaine will performe after placement laryngeal mask airway before surgery.

Intervention type: OTHER
Intervention: Transversus Abdominis Plane Block
Description: One-side ultrasound (US)-guided Transversus abdominis plane (TAP) block with 0.25% bupivacaine will performe after placement laryngeal mask airway before surgery.
Study: NCT05365425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline fenofibrate
Description: choline fenofibrate 178.8mg (135mg as fenofibric acid)
Study: NCT05066698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ST266
Description: Topical ocular application: one drop four times a day for eight weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.67% Sodium Chloride Ophthalmic Solution
Description: Topical ocular application: one drop four times a day for eight weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Open-label ST266
Description: Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Open-label ST266
Description: Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks
Study: NCT06512168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AAC Generative Language Intervention
Description: Aided AAC Language Input/Output Intervention
Study: NCT04845633

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the Effectiveness of Conventional Toothbrush in Dental Plaque Control in Healthy Children
Description: Healthy children will be given conventional toothbrush.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the Effectiveness of Customized Handle Toothbrush in Dental Plaque Control in Healthy Children
Description: Healthy children will be given toothbrush with Customized Handle.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the Effectiveness of Conventional Toothbrush in Dental Plaque Control in Children with Down Syndrome
Description: Children with Down syndrome will be given conventional toothbrush.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 week by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the Effectiveness of Customized Handle Toothbrush in Dental Plaque Control in Children with Down Syndrome
Description: Children with Down syndrome will be given toothbrush with Customized Handle.Plaque scores in groups will be assess pre-brushing and post-brushing in baseline, a week, and after 3 weeks by using the Turesky Modification of the Quigley-Hein Plaque Index (TMQHPI) for both buccal and lingual surfaces
Study: NCT05098613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19x22 CAR T Cells
Description: Autologous peripheral blood mononuclear cells transduced with CD19x22 CAR T lentiviral vector.
Study: NCT05509985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASKG315
Description: Injection with dose escalation stage of 3mg up to 45mg as well as dose expansion stage with recommended dose level from dose escalation stage.
Study: NCT05100485

Intervention type: DIAGNOSTIC_TEST
Intervention: Esophagogasrtoduodendoscopy
Description: Esophagogasrtoduodendoscopy was used to detech the presence of varices.

Intervention type: DIAGNOSTIC_TEST
Intervention: Esophagogasrtoduodendoscopy
Description: Esophagogasrtoduodendoscopy was used to detech the presence of varices.

Intervention type: DIAGNOSTIC_TEST
Intervention: Esophagogasrtoduodendoscopy
Description: Esophagogasrtoduodendoscopy was used to detech the presence of varices.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatic venous pressure gradient
Description: A method used to eveluate the portal pressure
Study: NCT05803590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Green tea mouthwash
Description: effictive against caries and periodontal diseases

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Green tea mouthwash
Description: effictive against caries and periodontal diseases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Description: the gold standard against which other anti-plaque and gingivitis agents are measured

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: the gold standard against which other anti-plaque and gingivitis agents are measured
Study: NCT04867889

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS (intermittent theta-burst stimulation)
Description: The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro X100 stimulator and a Cool-B65 A/P coil or a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The non-shielded side of the cool-B65 A/P coil is placed towards the patient, or if using the cool-B65 coil the centre of the butterfly is placed towards the patient head

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham iTBS
Description: The sham iTBS is delivered with MagPro X100 stimulator and a Cool-B65 A/P coil.~The coil is placed over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. For all patients electrodes for transcutaneous electrical nerve stimulation (TENS) are applied and if the patient is randomized to sham treatment the shielded side of the coil will be pointing towards the patient's head and there will be a weak TENS current applied instead synchoronously. If the cool-B65 is used the coil is instead angled 90 degrees delivering the pulses into air instead
Study: NCT05429151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd andcandida antigen
Description: Group 1: will be treated with intralesional injection of acyclovir (Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd) 250 mg acyclovir vial diluted with 3.5 ml saline to get approximately 70 mg/ml solution. During the study, the dosage of the drug and frequency of treatment were uniform in all patients. The base of each wart was injected with 0.1 ml of intralesional acyclovir (70 mg/ml) using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until the resolution of warts or for a maximum of 5 sessions~Group 2: will be treated by intralesional Candida antigen injection (candida antigen ) at a dose of 0.2 mL. injected into the largest wart using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 5 treatment sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd andcandida antigen
Description: Group 1: will be treated with intralesional injection of acyclovir (Acyclovir 250mg Powder for Solution for Infusion, each vial contains 250mg of acyclovir as the sodium salt, Chandra Bhagat Pharma Pvt. Ltd) 250 mg acyclovir vial diluted with 3.5 ml saline to get approximately 70 mg/ml solution. During the study, the dosage of the drug and frequency of treatment were uniform in all patients. The base of each wart was injected with 0.1 ml of intralesional acyclovir (70 mg/ml) using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until the resolution of warts or for a maximum of 5 sessions~Group 2: will be treated by intralesional Candida antigen injection (candida antigen ) at a dose of 0.2 mL. injected into the largest wart using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 5 treatment sessions.
Study: NCT06227663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KOALOU(®) digital application
Description: Digital app that prepares children for the ambulatory surgery care pathway by assessing their anxiety and educating them about anesthesia and surgery
Study: NCT05539859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Description: Subjects will receive surgical hematoma evacuation using neuroendoscope, followed by medical management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical management
Description: Subjects will initially receive the standard medical therapies for the treatment of intracerebral hemorrhage, according to the latest available guideline.
Study: NCT06010069

Intervention type: DIAGNOSTIC_TEST
Intervention: body temperature measurament
Description: body temperature of every patient was measured with tympanic thermometer during surgical procedure

Intervention type: DIAGNOSTIC_TEST
Intervention: body temperature measurament
Description: body temperature of every patient was measured with tympanic thermometer during surgical procedure

Intervention type: DIAGNOSTIC_TEST
Intervention: body temperature measurament
Description: body temperature of every patient was measured with tympanic thermometer during surgical procedure
Study: NCT06348368

Intervention type: OTHER
Intervention: Pentacam and autorefractometry
Description: Pentacam to detect corneal topographic changes. Auto-refractometry to assess refraction condition of the children

Intervention type: OTHER
Intervention: Pentacam and autorefractometry
Description: Pentacam to detect corneal topographic changes. Auto-refractometry to assess refraction condition of the children

Intervention type: OTHER
Intervention: Pentacam and autorefractometry
Description: Pentacam to detect corneal topographic changes. Auto-refractometry to assess refraction condition of the children
Study: NCT04850157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg, Q3W

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: 4 Gy\* 5 Fx,5Fx/Week
Study: NCT06087679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPS guided selfcare based intervention program
Description: Guided selfcare programme (Please refer to project description)
Study: NCT05372822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Burst Spinal Cord Stimulation
Description: Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Burst Spinal Cord Stimulation
Description: Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham spinal cord stimulation
Description: No spinal cord stimulation is provided

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham spinal cord stimulation
Description: No spinal cord stimulation is provided

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS implant
Description: a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Abbott will be implanted: ProclaimTM XR implantable pulse generator and Octrode® 8-contact lead

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SCS implant
Description: a subcutaneously implantable pulse generator (pacemaker) for long-term therapy.~The following system from Abbott will be implanted: ProclaimTM XR implantable pulse generator and Octrode® 8-contact lead
Study: NCT04833322

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-Galactose
Description: Galactose supplementation, once per day, up to 1.5g/kg per day
Study: NCT04532372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care drugs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care drugs

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT05879913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary CT Angiography (CCTA)
Description: Coronary computed tomographic angiography (CCTA) scan is a highly accurate noninvasive technique for detection of coronary artery plaque.
Study: NCT04994327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beta-glucan bread
Description: Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Beta-glucan bread
Description: Frozen bread is administered to the participants for home storage. Bread is thawed at home before consumption. Dosage: At least 3 slices of bread 6 days per week for 16 weeks
Study: NCT04897451

Intervention type: OTHER
Intervention: Questionnaire
Description: EQ5D-5L questionnaire self-reported 3 months after delivery
Study: NCT04769453

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Canaloplasty using the iTrack microcatheter with Healon GV Pro
Description: 360 degree microcatheterization and viscodilation of Schlemm's canal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Canaloplasty using the Omni surgical system with Healon GV Pro
Description: 360 degree microcatheterization and viscodilation of Schlemm's canal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Canaloplasty using the iTrack microcatheter with Healon Pro
Description: 360 degree microcatheterization and viscodilation of Schlemm's canal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Canaloplasty using the Omni surgical system with Healon Pro
Description: 360 degree microcatheterization and viscodilation of Schlemm's canal
Study: NCT04709380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus Toripalimab
Description: Intensity modulated radiotherapy has shown important role in the treatment of hepatocellular carcinoma (HCC), especially for advanced disease with portal vein tumor thrombosis (PVTT), or hepatic vein tumor thrombosis. Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib is a multi-targeted oral drug for the treatment of cancer.Treatment of inoperable advanced renal cell carcinoma ,inoperable or distant metastatic primary hepatocellular carcinoma and so on.